secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2023-10-13T23:59:59+00:00
Accession:  0001628280-23-034316
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma announces pediatric Vibativ safety study publication
----------------------------------------------------------------------

- First clinical study of Vibativ in children 2–17; single 10 mg/kg dose safe with no serious adverse events.
- Published in Antimicrobial Agents and Chemotherapy; 22 patients enrolled.
- Study found lower drug exposure in children vs adults, informing future dosing.
- Vibativ is FDA-approved for adult HABP/VABP and cSSSIs caused by gram-positive bacteria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023034316/0001628280-23-034316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828023034316/cpix-20231013.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-034316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer